Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02944435 · ClinicalTrials.gov registry record · Phase 1
A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults
A Phase 1 study, sponsored by Calithera Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT02944435 is a Phase 1 study that has completed, run by Calithera Biosciences. The registered enrollment target is 14 participants.
The verdict
NCT02944435, a Phase 1 study, has completed, sponsored by Calithera Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a Phase 1, randomized, single-dose, 2-way crossover PK comparability study of CB-839 administered as capsule and tablet formulations in healthy adult subjects.
Interventions
- DRUG CB-839 Capsules
- DRUG CB-839 Tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-10 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02944435
The ClinicalTrials.gov registry entry for NCT02944435 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calithera Biosciences, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CB-839 Capsules is the first listed.
NCT02944435 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02944435 about?
NCT02944435 is a clinical study titled "A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults". This is a Phase 1, randomized, single-dose, 2-way crossover PK comparability study of CB-839 administered as capsule and tablet formulations in healthy adult subjects.
What is the current status of trial NCT02944435?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2016-10. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02944435?
The interventions under investigation include: CB-839 Capsules (DRUG), CB-839 Tablets (DRUG).
Who is sponsoring clinical trial NCT02944435?
This trial is sponsored by Calithera Biosciences, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.